查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1916904

資生心氣丸市場：以劑型、銷售形式、通路、用途及最終用戶分類－2026-2032年全球預測

Ji Sheng Shen Qi Pills Market by Dosage Form, Selling Mode, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，志成新木丸市場規模為 1.104 億美元，預計到 2026 年將成長至 1.2298 億美元，年複合成長率為 5.95%，到 2032 年將達到 1.6554 億美元。

關鍵市場統計數據
基準年 2025 1.104億美元
預計年份：2026年 1.2298億美元
預測年份 2032 1.6554億美元
複合年成長率 (%) 5.95%

「Shisei Shinkigan」的策略定向是將傳統處方的傳承與現代分銷、監管和消費者健康趨勢相結合。

「濟生腎氣丸」佔據了傳統中醫與現代消費者健康需求交匯的獨特市場，代表著一個融合了數百年曆史的配方與現代分銷、監管和消費模式的品類。該產品吸引了專注於整合醫學的臨床醫生、尋求腎臟保健和氣血調理的消費者以及適應數位商業和嚴格品質標準的供應鏈利益相關相關人員的注意。要了解該產品，需要關注其植物成分的來源、生產的一致性、安全性監測以及行銷管道——如今，其銷售管道已從地方藥房擴展到全國醫院藥房和全球電商平台。

重大的產業發展趨勢重新定義了資生心氣丸在臨床和消費領域的產品品質、分銷策略和監管合規性。

「資生心氣丸」的市場格局正受到一系列變革的重塑，這些變革涵蓋了消費行為、監管預期以及不斷演變的通路。消費者日益要求產品具備產地資訊、成分標準化以及第三方安全檢驗，促使生產商加強對批次檢測、供應商審核和更清晰標籤的投入。同時，多個司法管轄區的監管機構正在提高草藥產品的監管標準，強調污染物控制、成分標籤的準確性以及能夠捕捉植物來源療法不利事件訊號的強化藥物監測系統。

2025年關稅調整和海關檢查力度加大對依賴進口草藥產品的採購計算、供應鏈韌性和商業性定價策略的影響

美國於2025年實施的貿易政策調整和關稅措施，進一步增加了草藥製劑及其成分跨境分銷的複雜性。雖然這些關稅針對的是特定的原料和包裝，而非成品，但其累積效應卻波及到最終成本、供應商選擇和策略採購等各個面向。依賴國際植物原料供應商的製造商面臨抉擇：要麼自行承擔額外關稅，要麼將成本轉嫁給經銷商，要麼將部分價值鏈轉移到其他地區。每種選擇都涉及不同的前置作業時間、資本投入和營運風險。

深度細分分析揭示了分銷管道、劑型、治療定位、商業性准入和終端用戶趨勢如何決定策略重點。

細分市場分析揭示了分銷管道、配方、治療定位、商業性准入以及終端用戶群體特徵如何共同影響資生心氣丸的需求模式和營運重點。從通路（包括醫院藥局、線上零售（含官網、公司自有行動應用和第三方電商平台）以及零售藥局）的角度來看，相關人員必須調整庫存時間、促銷方式和合規文件，以適應各通路的採購週期和信任訊號。醫院藥局負責人重視臨床證據和供應商信譽，零售藥局優先考慮貨架即用的包裝和麵向消費者的標籤，而線上零售商則要求強大的數位化認證和可靠的配送保障。

影響市場進入、文化接受度和分銷策略的區域趨勢和監管環境在美洲、歐洲、中東和非洲以及亞太地區各不相同。

「解腎丸」的區域市場趨勢反映了不同的管理體制、對傳統配方的文化接受度以及分銷基礎設施，所有這些因素都影響著商業性重點和打入市場策略。在美洲，整合醫學專業人士和尋求腎臟保健產品的消費者對「解腎丸」的認知度正在不斷提高，但市場准入需要嚴格的品質文件、進口合規性以及符合當地監管標準的清晰標籤。該地區的分銷主要由能夠證明分銷鏈控制和安全測試的認證供應商和零售合作夥伴主導，而線上管道則拓展了其在海外韓國人和專業醫療群體中的覆蓋範圍。

競爭格局概述：製造技術訣竅、證據創造和通路專業化如何創造差異化和韌性

「中藥材」領域的競爭格局呈現出多元化的特點，既有傳統中藥生產商，也有專業的代工生產商、垂直整合的出口商，以及利用D2C通路的數位化原生品牌。現有企業擁有許多優勢，例如植物原料採購網路、符合GMP標準的生產設施以及多年積累的監管文件，而新參與企業則透過臨床證據、創新劑型和注重可追溯性的高階品牌建設來脫穎而出。契約製造生產商能夠為希望外包生產並保持市場靈活性的品牌提供擴充性，但必須證明其具備處理植物原料和控制交叉污染的能力。

為製造商和經銷商提供切實有效的策略措施，以提高可追溯性、通路相容性和合應對力，同時保護利潤率。

產業領導者應優先考慮兼顧產品完整性、商業性擴充性和監管前瞻性的實際措施。首先，投資建造端到端的可追溯性系統，記錄植物成分的來源、批次檢測和供應商審核，以滿足進口商、機構買家和精通數位技術的消費者的需求。強大的可追溯性能夠減少海關和第三方檢驗的阻力，同時提升品牌信譽。其次，針對每個分銷管道最佳化市場推廣策略。為醫院藥房開發臨床文件和官方包裝，並為零售藥房最佳化面向患者的標籤和零售即用型SKU。為官方網站、行動應用程式和第三方電子商務平台建立數位認證、安全交付和客戶支援機制。

採用嚴謹的混合方法研究途徑，整合相關人員訪談、監管分析和供應鏈診斷，以獲得可操作的見解。

本研究整合了關鍵相關人員訪談、二手文獻綜述和供應鏈診斷，以全面了解再生新氣丸生態系統。主要數據透過與生產商、合約藥房、經銷商、醫院藥房採購負責人、零售品類經理和數位通路營運商的結構化訪談收集，以了解營運實踐和通路特定要求。二級資訊來源，包括監管指導文件、關於植物藥和安全性的學術文獻、進出口程序手冊和公共不利事件報告資料庫，用於驗證安全性和監管方面的相關主題。

策略重點綜合分析表明，品質、證據和管道差異化如何確保機構認可和消費者長期信任。

總之，資生心氣丸正處於一個戰略十字路口，傳統處方原則與日益成長的品質、透明度和合規性要求在此交匯。要獲得更廣泛的機構認可和永續的消費者成長，關鍵在於將傳統價值提案與現代生產實踐、可追溯性體系和基於證據的溝通相結合。積極關注採購流程完整性、分銷管道特定要求和監管文件合規性的相關人員，將更有能力應對關稅波動、海關檢查和不斷變化的消費者期望等挑戰。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 止痛藥丸市場按劑型分類

  • 膠囊
  • 顆粒
  • 藥片
  • 藥片

第9章：新木丸茂夫市場依銷售類型分類

  • 非處方藥
  • 處方箋

第10章：新木丸茂夫按分銷管道分類的市場

  • 醫院藥房
  • 線上零售
    • 官方網站
    • 專用行動應用
    • 第三方電子商務平台
  • 零售藥房

第11章 新木丸茂夫 按應用分類的市場

  • 一般健康維護
  • 腎臟健康
  • 氣虛

第12章：新木丸茂夫的最終用戶市場

  • 成人版
  • 對於老年人
  • 兒童

第13章：新木丸茂夫的區域市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 新木丸茂夫市集：依集團分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 新木丸茂夫 各國市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國重雄神奇丸市場

第17章：中國的五味參丸市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Beijing Tongrentang Co., Ltd.
  • China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
  • Guangzhou Pharmaceutical Holdings Limited
  • Guizhou Qilin Pharmaceutical Co., Ltd.
  • Harbin Pharmaceutical Group Co., Ltd.
  • Jilin Aodong Pharmaceutical Group Co., Ltd.
  • Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  • Tasly Pharmaceutical Group Co., Ltd.
  • Tianjin Zhongxin Pharmaceutical Group Corporation Limited
  • Yunnan Baiyao Group Co., Ltd.
Product Code: MRR-AE420CB153E4

The Ji Sheng Shen Qi Pills Market was valued at USD 110.40 million in 2025 and is projected to grow to USD 122.98 million in 2026, with a CAGR of 5.95%, reaching USD 165.54 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 110.40 million
Estimated Year [2026] USD 122.98 million
Forecast Year [2032] USD 165.54 million
CAGR (%) 5.95%

A strategic orientation to Ji Sheng Shen Qi Pills that connects traditional formulation heritage with contemporary distribution, regulation, and consumer health dynamics

Ji Sheng Shen Qi Pills occupy a distinctive niche at the intersection of traditional herbal practice and modern consumer health demand, representing a category where centuries-old formulations meet contemporary distribution, regulation, and consumption patterns. The product has drawn interest from clinicians focused on integrative care, consumers seeking kidney-support and qi-balancing remedies, and supply chain actors adapting to digital commerce and stricter quality standards. Understanding this product requires attention to botanical sourcing, manufacturing consistency, safety monitoring, and market channels that now extend beyond local apothecaries to national hospital pharmacies and global e-commerce platforms.

This introduction establishes the analytical frame for the report: physiological indications rooted in traditional medical paradigms, the modern implications for clinical and consumer adoption, and the operational challenges manufacturers and distributors face in ensuring quality, traceability, and regulatory compliance. The narrative that follows situates Ji Sheng Shen Qi Pills within shifting consumer health priorities, evolving regulatory scrutiny, and a distribution landscape that accommodates hospital pharmacy procurement, retail pharmacy stocking decisions, and an expanding suite of online retail touchpoints. By connecting formulation heritage with contemporary supply chain dynamics, readers will gain a practical orientation for interpreting subsequent sections on trade policy, segmentation, regional considerations, competitive dynamics, and actionable recommendations.

Critical industry forces redefining product integrity, channel strategy, and regulatory compliance for Ji Sheng Shen Qi Pills across clinical and consumer landscapes

The landscape for Ji Sheng Shen Qi Pills is being reshaped by a constellation of transformative shifts spanning consumer behavior, regulatory expectations, and channel evolution. Consumers are increasingly seeking products that demonstrate provenance, standardized composition, and third-party safety verifications, prompting manufacturers to invest in batch testing, supplier audits, and clearer labeling. Simultaneously, regulators in multiple jurisdictions have raised the bar for herbal products, emphasizing contaminant control, accurate ingredient declaration, and pharmacovigilance systems that can capture adverse-event signals for botanically derived therapies.

Channel dynamics are evolving in parallel. Traditional retail pharmacy networks continue to serve as a credibility gateway, while hospital pharmacy procurement is becoming more receptive to integrative therapies when supported by clinical evidence or formulary-level endorsements. Online retail is accelerating reach but also heightening the need for digital authenticity measures, controlled distribution of prescription-containing SKUs, and post-market customer support. Taken together, these trends demand that stakeholders balance heritage-driven product narratives with modern quality assurance, cross-channel consistency, and regulatory alignment to sustain both consumer trust and institutional acceptance.

How 2025 tariff shifts and heightened customs scrutiny have altered sourcing calculus, supply chain resilience, and commercial pricing strategies for import-dependent herbal products

Trade policy shifts and tariff measures enacted by the United States in 2025 have introduced additional layers of complexity to the cross-border movement of herbal formulations and their constituent raw materials. Even when tariffs target specific inputs or packaging elements rather than finished goods, the cumulative effect reverberates across landed costs, supplier selection, and strategic sourcing. Manufacturers that rely on international botanical suppliers have confronted choices between absorbing incremental duties, passing costs to distributors, or relocating portions of the value chain to alternative jurisdictions. Each pathway implies different lead times, capital expenditures, and operational risk profiles.

Indirect consequences have also emerged. Heightened tariffs and customs scrutiny can slow port throughput and increase documentary requirements, which in turn amplify working capital needs for inventory and expose perishable botanical inputs to quality deterioration risks. Regulatory documentation and certification burdens have intensified as importers seek to expedite customs clearance; firms investing in robust traceability and compliance documentation have experienced relatively smoother cross-border flows. The tariff environment has therefore incentivized players to diversify manufacturing footprints, strengthen supplier qualification programs, and explore nearshoring options where feasible, while trade-exposed distributors have reassessed pricing strategies and contractual terms to sustain margins and market access.

Deep segmentation analysis revealing how distribution channels, dosage formats, therapeutic positioning, commercial access, and end-user dynamics define strategic priorities

Segmentation insights reveal how distribution, formulation, therapeutic positioning, commercial access, and end-user demographics each shape demand patterns and operational priorities for Ji Sheng Shen Qi Pills. When viewed through distribution channel lenses such as hospital pharmacy, online retail-including official websites, proprietary mobile apps, and third-party e-commerce platforms-and retail pharmacy, stakeholders must calibrate inventory cadence, promotional approaches, and compliance documentation to match each channel's procurement cycles and trust signals. Hospital pharmacy buyers emphasize clinical evidence and supplier reliability, retail pharmacies prioritize shelf-ready packaging and consumer-facing claims, and online retail demands robust digital verification and fulfillment reliability.

Dosage form distinctions across capsules, granules, pills, and tablets materially influence manufacturing complexity, scalability, and consumer preference. Capsules and tablets offer dosing precision and shelf stability conducive to broader retail distribution, while granules appeal to consumers favoring traditional preparation methods and may require different storage and labelling approaches. Application segmentation across general wellness, kidney health, and qi deficiency drives messaging nuance: wellness positioning broadens appeal, kidney-focused claims raise the bar for clinical substantiation, and qi deficiency narratives often necessitate culturally contextual communication. Selling mode-over the counter versus prescription-affects channel eligibility, claims architecture, and regulatory reporting. End-user segmentation including adult, geriatric, and pediatric cohorts further informs formulation decisions, dosing guidance, and safety monitoring approaches, because each demographic group presents distinct pharmacological sensitivities, adherence behaviors, and caregiver involvement that must be addressed in product development and commercial plans.

Regional dynamics and regulatory contours that determine market access, cultural receptivity, and distribution strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics for Ji Sheng Shen Qi Pills reflect differing regulatory regimes, cultural acceptance of traditional formulations, and distribution infrastructure, all of which shape commercial priorities and go-to-market design. In the Americas, acceptance has been growing among integrative medicine practitioners and consumer segments seeking complementary kidney-support products, but market access is contingent on rigorous quality documentation, import compliance, and clear labeling that meets local regulatory standards. Distribution in this region often favors certified suppliers and retail partners who can demonstrate chain-of-custody and safety testing, while online channels have expanded reach among diaspora and specialty wellness communities.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory convergence varies across subregions and national frameworks. In parts of Europe, strict novel foods and herbal product rules require careful dossier preparation and sometimes localized clinical evidence, which influences market entry sequencing. Middle Eastern markets may show strong consumer interest where cultural familiarity with botanical remedies exists, yet import rules and halal-compliant documentation can be decisive. African markets offer both opportunity and complexity, with supply chain constraints and local regulatory capacity shaping partner selection. In the Asia-Pacific, cultural familiarity with traditional herbal medicines and established distribution networks in several countries enable broader consumer acceptance, but regional harmonization efforts and increased scrutiny of contaminants and heavy metals necessitate elevated quality controls and supplier transparency to support institutional adoption and cross-border trade.

Competitive landscape overview highlighting how manufacturing expertise, evidence generation, and channel specialization create differentiation and resilience

Competitive dynamics in the Ji Sheng Shen Qi Pills category are characterized by a mix of legacy herbal manufacturers, specialized contract formulators, vertically integrated exporters, and digitally native brands that leverage direct-to-consumer channels. Established manufacturers often possess advantages in botanical sourcing networks, GMP-capable facilities, and long-standing regulatory dossiers, while newer entrants differentiate through clinical evidence generation, novel dosage formats, or premium branding focused on traceability. Contract manufacturing organizations provide scalability for brands seeking to outsource production while retaining marketing agility, but they must demonstrate capability in botanical handling and cross-contamination controls.

Partnerships between clinical research groups and product developers have contributed to a rise in evidence-focused propositions, and distributors with robust cold chain and regulatory affairs teams have gained preferred status among institutional buyers. Digital platforms and third-party e-commerce marketplaces have lowered barriers to consumer access but require brands to prioritize anti-counterfeit measures, authenticated product listings, and post-sale support. Overall, companies that combine stringent quality systems, transparent supply chains, and channel-specific go-to-market capabilities are best positioned to navigate regulatory scrutiny and capture institutional and consumer trust.

Practical, high-impact strategic moves for manufacturers and distributors to strengthen traceability, channel fit, and regulatory readiness while protecting margins

Industry leaders should prioritize a set of actionable moves that align product integrity with commercial scalability and regulatory foresight. First, invest in end-to-end traceability systems that document botanical origin, batch testing, and supplier audits to satisfy importers, institutional buyers, and digitally savvy consumers. Robust traceability reduces the friction of customs and third-party verification while enhancing brand credibility. Second, tailor go-to-market strategies by channel: develop clinical dossiers and formal packaging for hospital pharmacy procurement, optimize patient-facing labeling and retail-ready SKUs for retail pharmacy, and implement digital authentication, fulfillment reliability, and customer support protocols for official websites, mobile apps, and third-party e-commerce platforms.

Third, diversify manufacturing and sourcing footprints where feasible to mitigate tariff exposure, port congestion, and single-supplier risk; nearshoring or dual-sourcing strategies can shorten lead times and improve quality oversight. Fourth, develop a pragmatic evidence roadmap that aligns claims with regulatory thresholds: invest in targeted clinical or real-world studies that support kidney-health and qi-related claims while ensuring adverse-event monitoring mechanisms are in place. Finally, strengthen commercial contracts and pricing frameworks to reflect increased supply-chain costs and compliance requirements, ensuring that distributor agreements and channel incentives preserve margin while maintaining affordability for key end-user segments like geriatric and pediatric populations.

Rigorous, mixed-method research approach integrating stakeholder interviews, regulatory analysis, and supply-chain diagnostics to derive actionable intelligence

This research synthesizes primary stakeholder interviews, secondary literature review, and supply-chain diagnostics to produce a balanced view of the Ji Sheng Shen Qi Pills ecosystem. Primary data were collected through structured discussions with manufacturers, contract formulators, distributors, hospital pharmacy procurement officers, retail category managers, and digital channel operators to capture operational realities and channel-specific requirements. Secondary sources included regulatory guidance documents, academic literature on botanicals and safety considerations, import/export procedural manuals, and public adverse-event reporting databases to triangulate safety and regulatory themes.

Analytical methods included comparative channel analysis to identify procurement and fulfillment differentials, supplier risk matrices to evaluate sourcing vulnerabilities, and scenario mapping to assess trade-policy impacts on lead times and landed compliance obligations. Quality assurance was assured through cross-validation of primary interview findings with documentary evidence from regulatory and industry standards. Throughout, emphasis was placed on actionable intelligence-linking operational levers such as manufacturing controls, documentation practices, and channel-specific packaging to observable outcomes in distribution, institutional acceptance, and consumer confidence.

A synthesis of strategic priorities showing how quality, evidence, and channel differentiation secure institutional acceptance and long-term consumer trust

In conclusion, Ji Sheng Shen Qi Pills sit at a strategic junction where heritage formulation principles meet heightened expectations for quality, transparency, and regulatory conformity. The path to broader institutional acceptance and sustainable consumer growth lies in harmonizing traditional value propositions with modern manufacturing practices, traceability systems, and evidence-aligned communication. Stakeholders that proactively address sourcing integrity, channel-specific requirements, and regulatory documentation will be better positioned to navigate tariff disruptions, customs scrutiny, and evolving consumer expectations.

Moving forward, the most resilient strategies blend operational investments-such as enhanced supplier qualification, diversified manufacturing footprints, and targeted clinical or real-world studies-with commercial adaptations tailored to hospital pharmacy, retail pharmacy, and online retail contexts. By aligning product stewardship with channel sophistication and regulatory preparedness, organizations can preserve the therapeutic heritage of Ji Sheng Shen Qi Pills while meeting the demands of contemporary health ecosystems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ji Sheng Shen Qi Pills Market, by Dosage Form

  • 8.1. Capsules
  • 8.2. Granules
  • 8.3. Pills
  • 8.4. Tablets

9. Ji Sheng Shen Qi Pills Market, by Selling Mode

  • 9.1. Over The Counter
  • 9.2. Prescription

10. Ji Sheng Shen Qi Pills Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Retail
    • 10.2.1. Official Website
    • 10.2.2. Proprietary Mobile App
    • 10.2.3. Third-Party E-Commerce Platform
  • 10.3. Retail Pharmacy

11. Ji Sheng Shen Qi Pills Market, by Application

  • 11.1. General Wellness
  • 11.2. Kidney Health
  • 11.3. Qi Deficiency

12. Ji Sheng Shen Qi Pills Market, by End User

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Ji Sheng Shen Qi Pills Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Ji Sheng Shen Qi Pills Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ji Sheng Shen Qi Pills Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Ji Sheng Shen Qi Pills Market

17. China Ji Sheng Shen Qi Pills Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Beijing Tongrentang Co., Ltd.
  • 18.6. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
  • 18.7. Guangzhou Pharmaceutical Holdings Limited
  • 18.8. Guizhou Qilin Pharmaceutical Co., Ltd.
  • 18.9. Harbin Pharmaceutical Group Co., Ltd.
  • 18.10. Jilin Aodong Pharmaceutical Group Co., Ltd.
  • 18.11. Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  • 18.12. Tasly Pharmaceutical Group Co., Ltd.
  • 18.13. Tianjin Zhongxin Pharmaceutical Group Corporation Limited
  • 18.14. Yunnan Baiyao Group Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL JI SHENG SHEN QI PILLS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL JI SHENG SHEN QI PILLS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GRANULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GRANULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GRANULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY OFFICIAL WEBSITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY OFFICIAL WEBSITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY OFFICIAL WEBSITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PROPRIETARY MOBILE APP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PROPRIETARY MOBILE APP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PROPRIETARY MOBILE APP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY THIRD-PARTY E-COMMERCE PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY THIRD-PARTY E-COMMERCE PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY THIRD-PARTY E-COMMERCE PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GENERAL WELLNESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GENERAL WELLNESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GENERAL WELLNESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY KIDNEY HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY KIDNEY HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY KIDNEY HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY QI DEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY QI DEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY QI DEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 130. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 132. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 150. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 153. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 157. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 160. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)